Finite mass-transfer boundary in drug release

ID: finite-mass-transfer-boundary-in-drug-release

A finite mass-transfer boundary in drug release represents a release surface whose receiving medium removes drug at a finite rate. The surface concentration can therefore exceed the bulk concentration. This is an alternative to imposing a perfect sink condition in drug release directly at the matrix surface.
Write the outward mass flux as
where is a transfer coefficient, is surface concentration and is bulk concentration on the same concentration scale. Combined with a diffusion equation inside the matrix, this is a Robin boundary condition: surface value and concentration gradient are coupled. If the two phases use different concentration scales, an appropriate partition relation is also needed rather than silently equating them.
A steady planar example makes the resistances explicit. Suppose a matrix layer of thickness has a maintained concentration at its inner face and constant diffusion coefficient . Then
The matrix resistance and external resistance add. This calculation assumes a maintained inner reservoir; it is not a complete transient solution for a depleting dosage form.
The mass-transfer Biot number for drug release compares those resistances:
For , and , and the flux is about of the negligible-external-resistance value. Doubling raises this to about ; it does not double the flux because matrix resistance remains.
The distinction is experimentally important. Increasing stirring, flow or membrane permeability tests whether receiving-side transport limits an observed release curve, although other experimental conditions must be controlled. The FDA’s primary adaptive-perfusion description specifically identifies passive dialysis-membrane transport as potentially rate-limiting and describes pressure-driven tangential filtration as an alternative.[ref] Small bulk concentration alone cannot establish negligible surface resistance.

New to topics? Read the docs here!